Perceptive Discovery Expands to Speed Next-Gen Cancer Drug Research

NEEDHAM, Mass. – April 02, 2026 – In a significant move to accelerate the fight against cancer, Perceptive Discovery today announced a major expansion of its laboratory capabilities at its Needham, Massachusetts facility. The investment dramatically scales up the company's capacity for preclinical oncology research, aiming to shorten the development timeline for the next generation of cancer therapies.

The expansion includes a five-fold increase in tissue culture space, a move that directly translates to a higher volume of simultaneous experiments and a greater capacity for complex, long-term studies. By integrating these enhanced in vitro capabilities with its established expertise, the scientific partner aims to provide biopharmaceutical companies with critical data earlier in the drug development process.

"This expansion reflects our continued commitment to provide the highest quality, decision-ready data for oncology drug development, at industry leading speed," said Ben Murphy, CEO of Perceptive Discovery, in a statement. "By significantly scaling our in vitro and ex vivo capabilities, we empower our partners with deeper biological insights earlier in development, saving critical time and resources, and ultimately accelerating the success of their programs toward effective cancer therapies."

Fueling the Race for Next-Generation Cancer Therapies

The strategic investment is timed to meet the explosive growth and specific needs of the most advanced areas in oncology. The global preclinical Contract Research Organization (CRO) market for oncology, valued at over $3 billion, is projected to more than double by 2032, driven by a robust pipeline of innovative drugs. Perceptive Discovery's expansion directly targets the complex requirements of these new therapeutic classes.

One of the most promising areas is radioligand therapy (RLT), which uses targeted molecules to deliver therapeutic radiation directly to cancer cells. This field, while growing rapidly, faces significant hurdles related to the complex handling and study of radioactive materials. The newly upgraded facility includes dedicated assay development laboratories for both radioactive and non-radioactive experimentation, positioning the company to better support the development of RLTs, including those using highly potent alpha emitters like Astatine-211.

Beyond radiopharmaceuticals, the expansion is built to support the development of other sophisticated treatments like biologics—including monoclonal antibodies and antibody-drug conjugates (ADCs)—and targeted small-molecule agents. These therapies require intricate in vitro models, such as 3D cell cultures and patient-derived organoids, to accurately predict their effects and identify patient populations most likely to benefit. The new specialized laboratory environments and enhanced engineering controls are designed specifically for these complex workflows.

An Integrated Approach in a Competitive Market

This expansion is not merely about adding space; it represents a strategic deepening of Perceptive Discovery's integrated service model. The company, part of the larger Perceptive organization formed by the 2024 merger of Calyx and Invicro, aims to differentiate itself in the highly competitive CRO landscape by offering a seamless, holistic approach to preclinical research. The global preclinical CRO market is expected to surpass $12 billion by 2033, with North America holding the largest share.

By strengthening its in vitro and ex vivo assay capabilities, the firm can now provide a more comprehensive data package that bridges early discovery with its existing strengths in in vivo imaging, radiochemistry, and dosimetry. For a biopharmaceutical client, this means data from a cellular assay can be more effectively correlated with results from an animal imaging study performed under the same roof, providing a clearer and more confident path forward.

This integrated workflow is designed to generate what the company calls "decision-ready data." In the high-stakes world of drug development, where failures in later stages can cost hundreds of millions of dollars, obtaining deeper biological insights early on is invaluable. By offering a more complete preclinical picture, the company enables its partners to make more confident go/no-go decisions, better identify potential challenges, and ultimately de-risk their programs before they enter human trials.

Inside the Expansion: More Than Just Square Footage

The tangible upgrades at the Needham site provide a clear picture of the enhanced capabilities. The five-fold increase in tissue culture space is the headline figure, but the specialized nature of the new labs is equally critical. The facility now features distinct, controlled environments for different stages of research.

This includes dedicated spaces for general tissue culture, quarantine areas for incoming cell lines to ensure purity, and clean-room processing suites for preparing pathogen-free cells. The latter is particularly crucial for creating reliable tumor inoculums used in in vivo animal studies, ensuring consistency and reproducibility from the lab bench to the preclinical model.

The investment also enables a broader range of critical assays, including radioligand binding and internalization studies, cellular phenotyping to understand a drug's effect on different cell types, and detailed mechanism-of-action analysis. This suite of tools is essential for building the comprehensive biological story required for regulatory submissions and for advancing a drug candidate with confidence.

Bolstering the Massachusetts Biotech Engine

Perceptive Discovery's investment also serves as another pillar supporting the Massachusetts life sciences corridor, a global epicenter for biotechnology and pharmaceutical innovation. The expansion not only adds to the region's advanced research infrastructure but also reinforces its reputation as a leader in oncology R&D.

The presence of a sophisticated, integrated CRO like Perceptive Discovery provides a significant advantage for the hundreds of local biotech startups and established pharmaceutical companies in the Boston/Cambridge hub. It gives them local access to cutting-edge preclinical services, which can foster closer collaboration and accelerate their own development pipelines.

While the company has not specified the number of new positions, such a major expansion typically brings high-skilled job growth, further strengthening the region's deep talent pool of scientists and technicians. By investing in the capacity to support the most advanced areas of cancer research, Perceptive Discovery is contributing to the ecosystem that makes Massachusetts a magnet for innovation, talent, and capital in the ongoing effort to develop more effective cancer treatments.